Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an apoptosis-inducing member of the TNF gene superfamily (Wiley et al., 1995; Griffith and Lynch, 1998) . TRAIL interacts with several distinct cell surface receptors including the death receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), and the decoy receptors, DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), as well as osteoprotegerin, which serve as an inhibitor of TRAIL-mediated apoptosis (Pan et al., 1997a, b; Emery et al., 1998) . Similar to TNF-R1 and Fas, DR4 and DR5 contain the intracellular death domain that is essential for the induction of apoptosis. TRAIL-induced activation of DR4 and DR5 involves the receptor multimerization with subsequent recruitment of several intracellular adaptor molecules to the death domain including Fas-associated death domain (FADD) and the initiator procaspase-8, which triggers cell death (Chaudhary et al., 1997; Schneider et al., 1997; Bodmer et al., 2000; Kischkel et al., 2000; Kuang et al., 2000; Sprick et al., 2000) . The activation of initiator caspase-8 can induce activation of the effector caspases in the cell death receptor pathway (Ashkenazi and Dixit, 1998) . The signaling events leading to apoptosis through the death receptors also involve the mitochondrial pathway (Green and Reed, 1998) , in which death signals lead to changes in mitochondrial membrane potential and membrane permeability, and the subsequent release of proapoptotic factors including cytochrome c (Liu et al., 1996) and second mitochondria-derived activator of caspase (Smac/DIABLO) (Du et al., 2000; Verhagen et al., 2000) . The cytosolic cytochrome c promotes caspase-9 activation and Smac/DIABLO downmodulates the apoptosis-inhibitory function of the proteins of the inhibitor of apoptosis (IAP) family such as X-linked IAP (XIAP) (Liu et al., 1996; Du et al., 2000; Verhagen et al., 2000) . Members of the Bcl-2 family, including antiapoptotic Bcl-2 and Bcl-X L , or proapoptotic Bax and Bid, are major regulators in the mitochondrial apoptosis pathway (Gross et al., 1999; Kroemer and Reed, 2000) . The interaction between pro-and antiapoptotic proteins may determine the susceptibility of cells to a death signal (Gross et al., 1999; Zhang et al., 2000) .
Unlike TNF-a and FasL, TRAIL appears to selectively induce apoptosis of transformed tumor cells (French and Tschopp, 1999) . The potential and safety of soluble TRAIL as an anticancer therapeutic agent has been demonstrated in mice and non-human primates (Ashkenazi et al., 1999; Walczak et al., 1999) . However, it has also been reported that certain forms of soluble TRAIL are able to induce apoptosis of normal human hepatocytes in vitro, which highlights concerns of potential toxicity in humans (Jo et al., 2000) . Recently, we have generated a novel agonistic anti-human DR5 monoclonal antibody, TRA-8, which induces apoptosis of most TRAIL-sensitive tumor cells both in vitro and in vivo (Ichikawa et al., 2001) . Unlike TRAIL, TRA-8 does not induce hepatocellular toxicity, indicating that specific targeting of DR5 with TRA-8 might be a safer and more effective strategy for cancer therapy than TRAIL.
There is increasing evidence showing that many chemotherapeutic agents have the ability to synergize TRAIL-mediated apoptosis of cancer cells both in vitro and in vivo (Gliniak and Keane et al., 1999; Mizutani et al., 1999 Mizutani et al., , 2001 Gibson et al., 2000; Yamanaka et al., 2000; Cuello et al., 2001; Hernandez et al., 2001; Lacour et al., 2001; Nagane et al., 2001; Frese et al., 2002) . However, the signaling mechanisms leading to synergistic induction of tumor cell apoptosis by such a combination are poorly understood. Recently, we found that bisindolylmaleimide VIII (Bis VIII), a death receptor signaling enhancer (Zhou et al., 1999) , enhances DR5-mediated apoptosis through the synergistic activation of the c-Jun N-terminal protein kinase (JNK)/p38 mitogen-activated protein kinase (MAPK) pathway and the mitochondrial death signaling pathway (Ohtsuka and Zhou, 2002) . Because the JNK/p38 signaling and the mitochondrial apoptosis pathways are crucially involved in cell death induced by many chemotherapeutic agents, we further examine the role of these two signaling pathway in synergistic induction of apoptosis of tumor cells with agonistic antibodies against DR4 and DR5 and chemotherapy agents. Our results demonstrate that the chemotherapy agents with the capability of inducing DNA damage, such as Adriamycin and Cisplatin, are able to synergistically enhance both anti-DR5 and DR4 antibody-induced apoptosis of several types of human tumor cells regardless of their pre-existing susceptibility to antideath receptor antibody-mediated apoptosis. Similar to those mediated by Bis VIII, the enhanced activation of the JNK/p38 kinase pathway and the mitochondrial apoptosis pathway appears to be a critical mechanism leading to synergistic induction of apoptosis by the combination of anti-death receptor antibody and chemotherapy agent.
Results
Enhanced cell death of tumor cells by combination of anti-death receptor antibody and chemotherapy agent DR4 and DR5 dual-positive MDA-MB-231-KS cells, a human breast cancer cell line, were examined for their susceptibility to TRAIL-, TRA-8-and 2E12-mediated apoptosis in the absence or presence of three commonly used chemotherapy agents, Adriamycin, Cisplatin and Taxol. In the absence of chemotherapy agents, the MDA-231 cells exhibited a different dose-dependent apoptotic response to TRAIL, TRA-8 and 2E12. Their susceptibility to apoptosis was high for TRA-8, intermediate for TRAIL and relatively low for 2E12 (Figure 1a) . The chemotherapy agent alone did not induce significant cell death at the indicated dose and period of time. However, among three tested chemotherapy agents, Adriamycin and Cisplatin but not Taxol significantly enhanced cell death induced by TRAIL, TRA-8 or 2E12. The synergistic effect of Adriamycin and Cisplatin on TRAIL receptor-mediated apoptosis was very similar to that induced by Bis VIII as previously shown (Ohtsuka and Zhou, 2002) . More complete cell death could occur with low doses of TRAIL (100 ng/ml) and TRA-8 (10 ng/ml) in the presence of 3 mm Adriamycin or 100 mm Cisplatin. While 100 ng/ml of 2E12 alone was unable to induce significant cell death, more than 60-70% cell death was induced by the same dose in the presence of Adriamycin or Cisplatin. Adriamycin appeared to be strong in the combination with TRA-8 as the susceptibility of cells to TRA-8-mediated apoptosis was increased more than 50-fold. The synergistic effect of Adriamycin and Cisplatin on TRA-8-induced apoptosis was dose-dependent ( Figure 1b ). Enhanced apoptosis of tumor cells by the combination treatment was evident as indicated by increased DNA fragmentation (Figure 1c ). When the cells were treated with chemotherapy agent (Adriamycin, Cisplatin, or Taxol) alone for long period of times (48-72 h), significant loss of cell viability was induced at lower concentrations of the agents (data not shown). Importantly, TRA-8 could still enhance the cell death induced by the chemotherapy agent in a synergistical manner (data not shown).
The synergistic effect of Adriamycin and Cisplatin on TRA-8-or 2E12-induced apoptosis was also examined in several other types of tumor cell lines including 2LMP (breast), HeLa (cervix), UL-3B (ovary), 1321N1 (astrocytoma) (Figure 2 ), and two colon (Widr and HT29) and two prostate cell lines (Du145 and PC-3) ( Table 1 ). All tested tumor cells became very susceptible to TRA-8-mediated apoptosis in the presence of either Adriamycin or Cisplatin regardless of their pre-existing sus-ceptibility to TRA-8 and chemotherapy agents. Although 2E12 was less effective in induction of apoptosis of tumor cells, the apoptotic response in two susceptible lines (2LMP and HeLa) was significantly enhanced by Adriamycin or Cisplatin. Taken together, these results indicate that Adriamycin and Cisplatin can synergistically enhance the death receptor-mediated apoptosis by enhancing the rate of cell death.
Enhanced caspase activation by combination of anti-death receptor antibody and chemotherapy agent To determine whether the synergistic induction of apoptosis by combination of anti-death receptor antibody and chemotherapy agent is through caspase pathway, the activation of three key caspases was examined by Western blot analysis. Treatment of MDA-MB-231-KS cells with low concentration of Death receptor antibodies and chemotherapy agents T Ohtsuka et al TRA-8 (10 ng/ml) or 2E12 (1000 ng/ml) did not induce strong cleavage of caspases-8, -9, and -3 ( Figure 3a) . As previously demonstrated, Bis VIII alone had little effect on the activation of caspases and cleavage of PARP. Although Adriamycin or Cisplatin alone induced a weak cleavage of caspase-9 and -3, the strong activation of all three caspases was only observed in the combination treatment with the anti-death receptor antibody (TRA-8 or 2E12) and the chemotherapy agent (Adriamycin or Cisplatin). The enhanced activation of caspases is indicated by decreased procaspase-8 and increased cleavage of caspase-9 and -3. The cleavage of PARP, a substrate for caspase-3, was also enhanced by the combination treatment. The synergistically induced cell death by the combination is also caspase-dependent as a caspase inhibitor, Z-VAD-FMK, significantly inhibited cell death (Figure 3b ). The similar caspase activation and dependence was also observed in 1321N1 and UL-3B cells treated with the combination of anti-death receptor antibody and chemotherapy agent (data not shown). Taken together, these results indicate that synergistic induction of apoptosis of tumor cells by anti-death receptor antibody and chemotherapy agent is through caspase pathway. The strong activation of caspase-8 and -9 suggests that both the initiator caspases are involved in the synergistic induction of apoptosis.
Synergistic activation of JNK/p38 pathway by combination of anti-death receptor antibody and chemotherapy agents
Our previous study has shown that Bis VIII enhances DR5-induced JNK/p38 through MKK4 activation (Ohtsuka and Zhou, 2002) . To examine the effect of chemotherapy agents on the activation of JNK/p38 during TRA-8-or 2E12-induced apoptosis, activation of these MAPK was determined by Western blot analysis with antibodies that recognize activated phosphorylated forms of these kinases. Treatment of MDA-MB-231-KS cells with Adriamycin or Cisplatin alone resulted in a mild activation of JNK and p38, similar to that with TRA-8 or 2E12 alone, which was significantly enhanced by the combination of either antibody with Adriamycin or Cisplatin (Figure 4a ). These effects resulted from increased phosphorylation of JNK and p38 rather than increased total amount of the protein (data not shown). In addition, these effects appear to be selective for JNK and p38, as the activation of a third member of this kinase family, ERK1/2, was not affected (Figure 4b ). These results indicate that the enhancement of apoptosis by Adriamycin or Cisplatin is associated with the synergistic activation of JNK/p38. To identify upstream kinase(s) for JNK and p38 activation, we examined the activation of three MAPK kinases, MKK4, which Death receptor antibodies and chemotherapy agents T Ohtsuka et al activates both JNK and p38, and MKK3 and -6, which only activate p38, during the treatment with TRA-8, 2E12, and chemotherapy agent. We found that only MKK4 and not MKK3/6 was activated by TRA-8, 2E12, or chemotherapy agents including Adriamycin and Cisplatin ( Figure 4a and data not shown). The combined treatment with the antibody and the chemotherapy agent resulted in a great increase in the activated MKK4 (Figure 4a ), suggesting that MKK4 is an upstream kinase responsible for DR4-, DR5-induced and chemotherapy agent-enhanced activation of JNK/p38. The synergistic activation of JNK/p38 by TRA-8 and chemotherapy agents was also observed in other types of tumor cells including astrocytoma, cervix, colon, and ovary (Table 1) . Similar to that observed in MDA-MB-231-KS cells, Adriamycin, Cisplatin, or Bis VIII alone was able to induce a mild activation of JNK/p38 in these cells (data not shown). However, the TRA-8-induced JNK/p38 activation was greatly enhanced in the presence of Adriamycin or Cisplatin. Importantly, the enhanced activation of JNK/p38 appeared to be associated with the increased susceptibility of tumor cells to anti-death receptor-mediated apoptosis. These results suggest that the JNK/p38 pathway might be a convergence point in the death receptor and chemotherapeutic agents-induced signal transduction leading to apoptosis.
To access the role of JNK/p38 in death process induced by death receptor antibody and chemotherapy agent, we used N-acetyl-l-cysteine (NAC) as an inhibitor for the JNK/p38 pathway as recent reports show that death receptor-mediated sustained activation of JNK and p38 is regulated by ASK1 , one of the MAPK kinase kinase family members, which can be inhibited by antioxidant such as NAC (Tobiume et al., 2001 ). As we expected, pretreatment with NAC effectively suppressed activation of JNK/p38, which was induced by either TRA-8 or chemotherapy agent alone or in combination (Figure 5a ). Correlated with the inhibitory ability to the JNK/p38 pathway, NAC was able to significantly inhibit cell death caspase-9 and -3 activation, and processing of Bid and PARP (Figure 5c ) induced by TRA-8 alone or a TRA-8 and chemotherapy agent combination. Since NAC was not able to or only partially inhibit caspase-8 processing induced by TRA-8 alone or a TRA-8 and chemotherapy agent combination (Figure 5c ), the caspase activation process was interrupted by NAC after activation of caspase-8 initiated by death receptor activation. Similar results were obtained in other cell lines including 1321N1 cells (data not shown). These results further support the notion that activation of JNK/p38 is involved in death receptormediated caspase activation and cell death.
Increased activation of mitochondrial apoptosis pathway by combination of anti-death receptor antibody and chemotherapy agent
Many apoptosis stimuli including the death-inducing ligands and chemotherapy agents can activate the mitochondrial apoptosis pathway. The loss of the mitochondrial membrane potential and the release of cytochrome c and Smac/DIABLO are the markers for the activation of mitochondrial pathway, which are regulated by the pro-and anti-apoptotic proteins of the Bcl-2 family (Green and Reed, 1998; Gross et al., 1999; Kroemer and Reed, 2000; Zhang et al., 2000) . To determine whether the mitochondrial pathway is involved in the enhancement of DR4-or DR5-induced apoptosis by chemotherapy agents, we first examined the alteration of mitochondrial membrane potential using a fluorescent dye, JC-1. Treatment of MDA-MB-231-KS cells with a low dose of TRA-8 or a higher dose of 2E12 alone led to a moderate loss of mitochondrial membrane potential (Figure 6a ). The chemotherapy agents alone including Adriamycin and Cisplatin, as well as Bis VIII, could induce a significant loss of mitochondrial membrane potential at a dose that was not sufficient to induce apoptosis. The complete loss of the mitochondrial membrane potential only occurred in In the mitochondrial pathway, the death signals lead to the release of proapoptotic factors including cytochrome c and Smac/DIABLO, which results in activation of caspase-9 and inactivation of IAPs, particularly XIAP, respectively (Liu et al., 1996; Du MDA-MB-231-KS cells were left untreated (N) or incubated with 3 mm Bis VIII (B), 3 mm Adriamycin (A), 100 mm Cisplatin (C), or 3 mm Taxol (T) in combination with 10 ng/ml TRA-8 or 1 mg/ml 2E12 plus 2 mg/ml crosslinker for 9 h. Whole-cell lysates were prepared and subjected to Western blot analysis using the respective antibodies as indicated. (b) MDA-MB-231-KS cells were preincubated with or without 10 mm Z-VAD-FMK for 1 h and then left untreated (None) or incubated with 3 mm Bis VIII (Bis), 3 mm Adriamycin (Adr), 100 mm Cisplatin (Cis), or 3 mm Taxol (Tax) in combination with indicated concentrations of either TRA-8 or 2E12 plus 2 mg/ml crosslinker for 14 h. Cell viability was determined by the ATPLite assay . To further evaluate the effect of chemotherapy agents on mitochondrial apoptosis signaling pathway, we examined the release of cytochrome c and Smac/DIABLO into cytosol in the presence or absence of death receptor signaling. The combination of TRA-8 and Adriamycin induced more release of cyto-chrome c and Smac/DIABLO than any single treatment, which was well correlated with the loss of mitochondrial membrane potential (Figure 6b ). The expression and cleavage of several key proteins related to the mitochondrial death pathway was examined by Western blot analysis. The cleavage of Bid, a substrate of caspase-8, was enhanced by the combination of a low dose of TRA-8 with Adriamycin or Cisplatin (Figure 6c ), sugg-esting that the death pathway from caspase to mitochondria was activated by the combination. The Bcl-X L , an antiapoptosis protein was cleaved from 30 kDa into 16-kDa fragment in a caspase-dependent fashion, which was blocked by Z-VAD-FMK (Figure 6d ). The 16 kDa cleavage product of Bcl-X L has been shown to involve acceleration of cell death (Clem et al., 1998) . The activation of caspase-9 was enhanced as well ( Figure 6c ). In contrast, the levels of XIAP and Bax did not significantly change by the treatment. These results indicate that the combination treatment leads to a shift from antiapoptosis to proapoptosis by altering the function of the proteins in the Bcl-2 family, which contributes to enhanced release of cytochrome c and Smac/DIABLO from mitochondria.
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Discussion
There is accumulating evidence suggesting that synergistic induction of apoptosis with TRAIL and chemo- 2001). However, the synergistic mechanisms by which chemotherapy agents enhance the death receptor-mediated apoptosis are not fully understood. It has been difficult to examine specifically the death receptor-mediated signal transduction using TRAIL because many receptors for TRAIL complicate the signal transduction. The availability of TRA-8 and 2E12 allows us to determine the susceptibility of tumor cells to DR5-and DR4-mediated apoptosis without the interference of the decoy receptors. Our previous study demonstrates that the expression levels of DR5 are not necessarily correlated with its apoptosis-inducing function (Ichikawa et al., 2001) . Although many cancer cells can express high levels of cell surface DR4 and DR5, their susceptibility to the death receptor-mediated apoptosis varies largely, suggesting that the intracellular control of the death receptor signal transduction is likely a key to induction of apoptosis by anti-death receptor antibody. Thus, identification of the synergistic strategy and mechanisms would be important for the future development of TRAIL and anti-death receptor antibody based anticancer therapy. In the present study, we utilized two agonistic monoclonal antibodies against DR4 and DR5 to demonstrate the death signal transduction by DR4 and DR5 and the manipulation by chemotherapy agents. Our results indicate that Adriamycin and Cisplatin can significantly enhance apoptosis induced by anti-death receptor antibodies, and the synergistic activation of the JNK/p38 kinase pathway and the mitochondrial death pathway are crucial mechanisms for enhanced apoptosis. In the previous studies, we have demonstrated that the synergistic activation of both the JNK/p38 kinase pathway and the mitochondrial death pathway plays a crucial role in the synergistic induction of apoptosis of tumor cells by combination of TRA-8 and Bis VIII, a death receptor signaling enhancer (Ohtsuka and Zhou, 2002) . These results promoted us to examine the synergistic effect of chemotherapy agents on DR5 and DR4-mediated apoptosis. Our results suggest that in the presence of DR4 or DR5 signaling, the activation of JNK/p38 controls the process of apoptosis. 2E12-or TRA-8-induced apoptosis was accompanied by 8 for 4 h. Whole-cell lysates were prepared and subjected to Western blot analysis using antibodies to phospho-JNK46/54 ( p -JNK), or phospho-p-38 ( p -p38). Fold stimulation was determined by densitometric scanning of respective bands on the blots and plotted as graphs. (b) MDA-MB-231-KS cells were preincubated with or without 10 mm NAC for 1 h and then left untreated (None) or incubated with 3 mm Bis VIII (Bis), 3 mm Adriamycin (Adr), 100 mm Cisplatin (Cis), or 3 mm Taxol (Tax) in combination with indicated concentrations of TRA-8 for 14 h. Cell viability was determined by the ATPLite assay. (c) MDA-MB-231-KS cells were preincubated with or without 10 mm NAC for 1 h and then left untreated (N) or incubated with 3 mm Bis VIII (B), 3 mm Adriamycin (A), 100 mm Cisplatin (C), or 3 mm Taxol (T) in combination with indicated concentrations of TRA-8 for 9 h. Whole-cell lysates were prepared and subjected to Western blot analysis using the respective antibodies as indicated Death receptor antibodies and chemotherapy agents T Ohtsuka et al induction of caspase processing ( Figure 3a ) and activation of JNK/p38 ( Figure 4a and Table 1 ), which was mediated by an upstream kinase MKK4 (Figure 4a ). Adriamycin or Cisplatin clearly enhanced 2E12-or TRA-8-induced cell death (Figures 1 and 2 , and Table 1) by facilitating the caspase activation (Figure 3 ) in parallel with an increase in the activation of the MKK4/JNK/p38 pathway ( Figure 4a and Table 1 ). Since 2E12-or TRA-8-induced activation of JNK/p38 was strongly inhibited by caspase-8 inhibitor (Ohtsuka and Zhou, 2002) , there might be a positive interaction between caspase-8 and the JNK/p38, which triggers an amplification loop between caspase cascade and the JNK/p38 pathway. DR4 or DR5 signaling initiates a weak activation of MKK4/JNK/p38 through caspase-8, and in this event, enhanced activation of JNK/p38 by chemotherapy agents further leads to activation of caspase-8 and downstream caspases and then enhancement of apoptosis. The inhibition of the JNK/p38 pathway by NAC antagonizes both the enhancing effect of chemotherapy agent on death-receptor-induced caspase activation and cell death ( Figure 5 ). Since NAC was able to inhibit strongly activation of both JNK/p38, downstream caspases and Bid processing but not caspase-8 processing induced by TRA-8 or a TRA-8 and chemotherapy agent combination, prolonged activation of JNK/p38 activation may play a role for enhancement of caspase activation process and Bid cleavage after processing of caspase-8 initiated by death receptor activation. Close correlation between enhanced activation of JNK/p38 and the synergistic induction of DR4-or DR5-mediated caspase activation and apoptosis by chemotherapy agents as well as Bis VIII suggests that the signal transduction triggered by these agents might merge at JNK/p38. In the present study, we also demonstrated the significance of mitochondrial apoptosis signaling in enhancement of death receptor-mediated apoptosis by chemotherapy agents. Similar to Bis VIII, treatment of cells with chemotherapy agents including Adriamycin or Cisplatin alone resulted in loss of mitochondrial membrane potentials (Figure 6a and b) . In addition, Adriamycin alone induced a weak release of cytochrome c and Smac/DIABLO, suggesting that mitochondria is likely one of the targets of chemotherapy agents as reported previously (Decaudin et al., 1997; Kidd et al., 2002; Sartorius and Krammer, 2002) . Thus, the mitochondrial apoptosis pathway through cytochrome c and Smac/DIABLO releases is a crucial convergence point triggered by death receptors and chemotherapy agents such as Adriamycin and Cisplatin as well as Bis VIII. The loss of mitochondrial membrane potential by Bis VIII or chemotherapy agents might be able to sensitize the cells to death receptor-mediated apoptosis by enhancing utilization of the mitochondrial apoptosis pathway. Activated JNK/p38 might be able to regulate mitochondrial pathway through cleavage of Bid by enhanced activation of caspase-8, phosphorylation of Bcl-2 and Bcl-X L for functional inactivation (Maundrell et al., 1997; Yamamoto et al., 1999; Kharbanda et al., 2000) , and/or direct activation of mitochondrial death machinery (Aoki et al., 2002) .
In conclusion, we propose a model in which a positive interaction between the JNK/p38 pathway and caspase activation cascade though caspase-8 and mitochondrial pathway leads to enhanced apoptosis signal transduction. Two death signal pathways initiated by death receptors and chemotherapy agents merged at the JNK/ p38 kinases and mitochondria, which in turn synergistically enhances the caspase-8 and mitochondrial death signal transduction, leading to more complete cell death in tumor cells. Thus, the simultaneous targeting of cell surface death receptors with agonistic monoclonal antibodies and the intracellular JNK/p38 and mitochondrial pathways with chemotherapy agents would be an important strategy for more effective anticancer therapy.
Materials and methods
Reagents
An agonistic anti-human DR4 monoclonal antibody, 2E12, was generated by Ichikawa et al. (TRAIL R2 (DR5) is a novel, selective therapeutic target for rheumatoid arthritis, submitted for publication). An agonistic anti-human DR5 monoclonal antibody, TRA-8, was prepared as described (Ichikawa et al., 2001) . Bis VIII, Adriamycin, Cisplatin, Taxol, and recombinant soluble TRAIL were purchased from Alexis Biochemicals (San Diego, CA, USA). The caspase inhibitor Z-VAD-FMK was from R&D Systems, Inc. (Minneapolis, MN, USA), Nacetyl-l-cysteine (NAC) was from Sigma, and 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1) were from Molecular Probes, Inc. (Eugene, OR, USA). Anti-phospho-JNK (Thr183/Tyr185), anti-phosphop38 MAPK (Thr180/Tyr182), anti-phospho-extracellular signal-regulated protein kinase (ERK) 1/2 (Thr202/Tyr204), anti-phospho-MAPK kinase 4 (MKK4) (Thr261), anti-Bid, anti-Bax, anti-Bcl-X L , anti-XIAP, and anti-poly (ADP-ribose) polymerase (PARP) antibodies, and horseradish peroxidaselinked anti-rabbit IgG were from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-caspase-3, -8, -9 and anticytochrome c antibodies were from PharMingen (San Diego, CA, USA), and horseradish peroxidase-linked anti-mouse IgG was from Amersham Pharmacia Biotech (Piscataway, NJ, USA). Anti-Smac/DIABLO, antiactin, and horseradish peroxidase-linked goat anti-mouse IgM were from Oncogene (Boston, MA, USA).
Cell culture and cell viability assay MDA-MB-231-KS, MDA-MB-231-PO, and 2LMP cells were isolated by subcloning from parental MDA-MB-231 cell line purchased from the American Tissue Culture Collection (ATCC) (Manassas, VA, USA), and maintained at 371C in a humidified atmosphere of 5% CO 2 in air in DMEM medium supplemented with 10% heat-inactivated (561C for 30 min) fetal calf serum (FCS), 50 mg/ml streptomycin, and 50 U/ml penicillin (all from Cellgro, Mediatec, Inc., Herndon, VA, USA). Human 1321N1 astrocytoma cells were kindly provided by Dr Richard Jope (University of Alabama at Birmingham), and maintained in DMEM medium supplemented with 5% heat-inactivated FCS, and antibiotics as described above. Human ovarian cancer cell lines, UL-3B and UL-3C, were kindly provided by Dr Cicek Gercel Taylor (University of Louisville) and maintained in RPMI1640 medium supplemented with 10% heat-inactivated FCS. All other cell lines were purchased from ATCC (Manassas, VA, USA) and grown in culture according to the instructions provided with them.
For cell viability assay, cells (1-2 Â 10 3 cells/well) were seeded onto 96-well plate in a volume of 50 ml. The caspase inhibitors were added 1 h before addition of stimulants. After incubating the cells for indicated periods, cell viability was determined using the ATPLite kit according to the manufacture's instructions (Packard Instruments, Meriden, CT, USA).
Western blot analysis
After the required treatments, cells (1-3 Â 10 6 ) were washed once with phosphate-buffered saline and lysed in the sample buffer (100-120 ml) for SDS-polyacrylamide gel electrophoresis (PAGE) and immediately boiled for 4 min. To measure the release of cytochrome c and Smac/DIABLO from mitochondria, cytosolic fraction was prepared using the Mitochondrial/ Cytosol Fractionation Kit according to the manufacturer's instructions (Alexis Biochemicals, San Diego, CA, USA). Each sample was subjected to 8 or 12.5% SDS-PAGE, and the proteins separated in the gel were subsequently electrotransferred onto a polybinylidene difluoride membrane (MILLI-PORE, Bedford, MA, USA). The membrane was blocked with 5% nonfat dry milk in TBS-T (20 mm Tris-HCl (pH 7.4), 8 g/l NaCl, and 0.1% Tween 20) for 1-2 h at room temperature. The membrane was then incubated with indicated primary antibodies in TBS-T containing either 5% nonfat dry milk or 5% bovine serum albumin at 41C overnight. The membrane was washed three times with TBS-T and probed with peroxidase-conjugated secondary antibodies at room temperature for 1.5 h. After washing four times with TBS-T, the protein was visualized using the ECL Plus Western blotting detection system (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Proteins were quantified by densitometric analysis using Quantify One program (Bio-Rad Laboratories, Hercules, CA, USA).
DNA fragmentation assay
After the required treatments of cells (1 Â 10 6 ), both adherent and detached cells were collected as described above, washed once with phosphate-buffered saline, lysed in 100 ml of TE-T buffer containing 10 mm Tris-HCl (pH 7.4), 10 mm EDTA, and 0.5% Triton X-100. Lysates were centrifuged at 14 000 r.p.m.
for 5 min at 41C and supernatants were then subjected to digestion with ribonuclease A (0.2 mg/ml) for 1 h at 371C followed by incubation with proteinase K (0.2 mg/ml) for 1 h at 371C. DNA in the sample was precipitated by centrifugation at 14 000 r.p.m. for 15 min at 41C after treatment with 50% isopropanol and 0.5 m NaCl overnight at À201C. DNA was resuspended in 30 ml of TE buffer and analysed by electrophoresis on 2% agarose gel in the presence of 0.2 mg/ml ethidium bromide.
Determination of mitochondrial membrane potential
The mitochondrial membrane potential was assessed by using JC-1, a lipophilic cation that can selectively enter into mitochondria (Reers et al., 1991) . JC-1 was dissolved in dimethylsulfoxide to give a 1 mg/ml solution. This was further diluted to 20 mg/ml in a FACS buffer containing 5% FCS and 0.1% NaN 3 in phosphate-buffered saline, and filtered using 0.45-mm filter. After the required treatments of cells (2 Â 10 5 ), both adherent and detached cells were collected as described above and resuspended in 125 ml of the FACS buffer. The cell suspension was incubated for 20 min at room temperature with 250 ml of the filtered working solution of JC-1. Both red and green fluorescence emissions were analysed with a flow cytometer (FACScan, Becton Dickinson, Sunnyvale, CA, USA). A minimum of 10 000 cells per sample was acquired in list mode and analysed using Winmdi software. The decrease in mitochondrial membrane potential was determined by a decrease in the ratio of red to green fluorescence intensities.
